Loading organizations...
§ Private Profile · Tshwane, South Africa
Preclinical biotech developing a universal donor cell platform for off-the-shelf cell therapies, minimizing immune rejection.
Altera Biosciences is a preclinical-stage biotechnology company developing a universal donor cell platform, based in Pretoria and Cape Town, South Africa. The organization utilizes proprietary gene silencing technology to remove specific identity markers on donor cells, minimizing immune rejection and enabling off-the-shelf cell therapies. This therapeutic approach directly addresses complex donor-recipient matching challenges within genetically diverse populations for severe medical conditions like diabetes, cancer, and transplant rejection. The startup recently raised R29 million, or approximately $1.6 million, in a pre-seed funding round led by venture capital firms OneBio Venture Studio and E Squared Investments. Operating within the regenerative medicine sector, the enterprise leverages scientific research connections with the University of Pretoria to advance its preclinical biopharmaceutical development initiatives. The biotechnology company was founded by entrepreneur Alexandra Miszewski and scientific researcher Michael Pepper.
Altera Biosciences has raised $1.6M across 1 funding round.
Altera Biosciences has raised $1.6M in total across 1 funding round.
Altera Biosciences has raised $1.6M in total across 1 funding round.
Altera Biosciences's investors include Allan Gray E-Squared Ventures, OneBio.
Altera Biosciences has raised $1.6M across 1 funding round. Most recently, it raised $1.6M Pre-Seed in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 7, 2025 | $1.6M Pre Seed | — | Allan Gray E Squared Ventures, Onebio | Announced |